Overview:Endo International plc is a global specialty pharmaceutical company focused on improving the lives of patients
while creating value. Endo develops, manufactures, markets and distributes quality branded and generic
pharmaceutical products as well as over-the-counter medications through our operating companies –
Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, SOMAR and Litha. Endo commenced
operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from
The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include
the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals
and International Pharmaceuticals.
Endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating
model with focused and disciplined execution that allows us to pursue growth opportunities
both organically and through selective acquisitions. Additionally, we are leveraging a research
and development model that focuses on lower risk, near-term projects. Our goal is to
consistently create value for our shareholders while serving our patients and customers.
Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania.
We employ approximately 6,000 people worldwide*. For more information about Endo International
and our operating companies, please visit www.endo.com.
*as of 11/30/2015